EUDA / EUDA Health Holdings Limited - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio

Exhibit 99.1 EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio SINGAPORE, Sept. 04, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced that it has secured distribution rights

EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd

Exhibit 99.1 EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the “LOI”) to potentially acquire Chem

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-406

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979. (

EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement

Exhibit 99.1 EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) - EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., h

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-406

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-06 One Pemimpin Singapore 576151 (Address

EUDA HEALTH HOLDINGS LIMITED US$10,000,000 Convertible Note Up to 5,000,000 Ordinary Shares issuable upon conversion of the $10,000,000 Convertible Note

Filed Pursuant to Rule 424(b)(5) Registration No. 333-282723 PROSPECTUS SUPPLEMENT (To Prospectus dated November 4, 2024) EUDA HEALTH HOLDINGS LIMITED US$10,000,000 Convertible Note Up to 5,000,000 Ordinary Shares issuable upon conversion of the $10,000,000 Convertible Note We are offering, in a registered direct offering to Indigo Capital LP, an accredited investor (the “Investor”), one or more c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A Amendment No. 1 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 60 Kaki Bukit Place, #03-01 Eunos Techpark Si

EUDA HEALTH HOLDINGS LTD. CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT

Exhibit 1.1 EUDA HEALTH HOLDINGS LTD. CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT This CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (this “Agreement”) is made as of August 1, 2025, by and between EUDA HEALTH HOLDINGS LTD., a company organized under the laws of British Virgin Islands (the “Company”), and Indigo Capital LP, a limited partnership organized under the laws of the Cayman Islands (t

CONVERTIBLE PROMISSORY NOTE

Exhibit 1.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-406

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 60 Kaki Bukit Place, #03-01 Eunos Techpark Singapore 415979 (Ad

AT THE MARKET OFFERING AGREEMENT June 23, 2025

Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT June 23, 2025 Chardan Capital Markets 1 Pennsylvania Plaza Suite 4800 New York, NY 10119 Ladies and Gentlemen: EUDA Health Holdings Limited, a corporation organized under the laws of the British Virgin Islands (the “Company”), confirms its agreement (this “Agreement”) with Chardan Capital Markets LLC (the “Sole Manager” or “Manager”) Definitions. The te

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40678

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 60 Kaki Bukit Place, #03-01 Eunos Techpark Singapore 415979 (Addr

EUDA HEALTH HOLDINGS LIMITED Ordinary Shares

FILED PURSUANT TO RULE 424(b)(5) REGISTRATION NO. 333-282723 PROSPECTUS SUPPLEMENT (to Prospectus dated November 4, 2024) $10,000,000 EUDA HEALTH HOLDINGS LIMITED Ordinary Shares We entered into an At The Market Offering Agreement (the “Sales Agreement”) dated June 23, 2025 with Chardan Capital Markets, LLC (“Chardan” or “Agent”), relating to our ordinary shares offered by this prospectus suppleme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-40678

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 60 Kaki Bukit Place, #03-01 Eunos Techpark Singapore 415979 (Addre

DATED THIS ____th day of ___________ Lim Alfred (the “Lender”) EUDA Health Holdings Limited (the “Borrower”) LOAN AGREEMENT

Exhibit 10.21 DATED THIS th day of Between Lim Alfred (the “Lender”) And EUDA Health Holdings Limited (the “Borrower”) LOAN AGREEMENT This LOAN AGREEMENT is made the day of BETWEEN:- (1) LIM ALFRED (NRIC No. S0028833J) of 10 Marlene Avenue Singapore 556622 (the “Lender”); and (2) EUDA Health HOLDINGS Limited, a company incorporated in the British Virgin Islands and having its registered office at

LOAN EXTENSION AGREEMENT

Exhibit 10.24 LOAN EXTENSION AGREEMENT This LOAN EXTENSION AGREEMENT is made the 1st day of April 2025 BETWEEN: (1) 8I ENTERPRISES PTE LTD, a company incorporated in Singapore and having its office at 6, Eu Tong Sen Street, #08-13 The Central, Singapore 059817 (hereinafter referred to as the “Creditor”); and (2) EUDA HEALTH HOLDINGS LIMITED, a company incorporated in the British Virgin Islands and

LOAN EXTENSION AGREEMENT

Exhibit 10.23 LOAN EXTENSION AGREEMENT This LOAN EXTENSION AGREEMENT is made the 1st day of April 2025 BETWEEN: (1) LIM ALFRED (NRIC No. S0028833J) of 10 Marlene Avenue, Singapore 556622 (hereinafter referred to as the “Creditor”); and (2) EUDA HEALTH HOLDINGS LIMITED, a company incorporated in the British Virgin Islands and having its registered office at Clarence Thomas Building, P.O. Box 4649,

THIS SUPPLEMENTAL AGREEMENT

Exhibit 10.20 THIS SUPPLEMENTAL AGREEMENT is made on 30th day of June 2024 BETWEEN: 1. LIM ALFRED (NRIC No. S0028833J) of 10 Marlene Avenue, Singapore 556622 (the “Lender”); and 2. EUDA HEALTH HOLDINGS LIMITED (Company Number 2053029), a company incorporated in the British Virgin Islands and having its registered office at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin

EX-10.25

Exhibit 10.25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E

DATED THIS ____ DAY OF ______ 8i Enterprises Pte Ltd (the “Lender”) EUDA Health Holdings Limited (the “Borrower”) LOAN AGREEMENT

Exhibit 10.22 DATED THIS DAY OF Between 8i Enterprises Pte Ltd (the “Lender”) And EUDA Health Holdings Limited (the “Borrower”) LOAN AGREEMENT This LOAN AGREEMENT is made the day of BETWEEN:- (1) 8I Enterprises Pte Ltd, a company incorporated in Singapore and having its office at 6, Eu Tong Sen Street, #08-13 The Central, Singapore 059817 (hereinafter referred to as “Lender’ (the “Lender”); and (2

EUDA HEALTH HOLDINGS LIMITED CLAWBACK POLICY

Exhibit 97 EUDA HEALTH HOLDINGS LIMITED CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of EUDA Health Holdings Limited (formerly known as 8i Acquisition 2 Corp.

EUDA HEALTH HOLDINGS LIMITED Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities

Exhibit 4.1 EUDA HEALTH HOLDINGS LIMITED Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities This Policy provides guidelines to employees, executive officers and directors of, and consultants and contractors to EUDA Health Holdings Limited (the “Company”) with respect to transactions in the Company’s securities. Applicability of Policy This Policy appli

EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia

Exhibit 99.1 EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia April 24, 2025 07:00 ET | Source: EUDA Health Holdings Ltd SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) – EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-in

EX-10.2

Exhibit 10.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-4067

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979 (Ad

EX-10.1

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 60 Kaki Bukit Place #03-01 Eunos Techpark, Singapore 415979 (

EUDA Holdings and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation - Preliminary Discussions Underway to Establish a Joint Venture

Exhibit 99.1 EUDA Holdings and Guangdong Cell Biotech Explore Potential Strategic Partnership to Advance Biotechnology Innovation - Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE, December 16, 2024 /Globenewswire/ — EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-06 One Pemimpin Singapore 576151 (Addres

EUDA HEALTH HOLDINGS LIMITED 1 Pemimpin Drive #12-06 One Pemimpin Singapore 576151

EUDA HEALTH HOLDINGS LIMITED 1 Pemimpin Drive #12-06 One Pemimpin Singapore 576151 October 31, 2024 VIA EDGAR U.

As filed with the Securities and Exchange Commission on October 30, 2024

As filed with the Securities and Exchange Commission on October 30, 2024 Registration Statement No.

OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023

Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023 In this report, as used herein, and unless the context suggests otherwise, the terms “EUDA,” “Company,” “we,” “us” or “ours” refer to the combined business of Euda Health Holdings Limited and its subsidiaries

As filed with the Securities and Exchange Commission on October 18, 2024

As filed with the Securities and Exchange Commission on October 18, 2024 Registration Statement No.

Calculation of Filing Fee Tables Form F-3 (Form Type) EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(3) Fee Rate Amount of Re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-06 One Pemimpin Singapore 576151 (Address

EUDA HEALTH HOLDINGS LIMITED Dated as of ________, 20__ Debt Securities TABLE OF CONTENTS ARTICLE 1

  Exhibit 4.7 EUDA HEALTH HOLDINGS LIMITED AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS ARTICLE 1 ARTICLE 1 DEFINITIONS 1 Section 1.01 Definition of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sec

EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

Exhibit 99.1 EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2024 2023 ASSETS CURRENT ASSETS Cash $ 376,206 $ 189,005 Accounts receivable, net 176,988 237,474 Prepayments 150,966 - Other receivables 19,293 1,711 Other receivable, related party 20,557 - Other receivable 20,557 - Prepaid expenses and other current assets 207,358 192

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-06 One Pemimpin Singapore 576151 (Address

EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES Unaudited Pro Forma Condensed Combined Balance Sheet As of December 31, 2023

Exhibit 99.2 EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES Unaudited Pro Forma Condensed Combined Balance Sheet As of December 31, 2023 EUDA FCL Transaction Accounting Adjustments Pro Forma Combined ASSETS CURRENT ASSETS Cash $ 189,005 $ 10,812 $ - $ 199,817 Accounts receivable, net 237,474 - - 237,474 Prepaid expenses and other current assets 194,123 - - 194,123 Current assets of discontinued ope

FORTRESS COVE LIMITED INDEX OF FINANCIAL STATEMENTS

Exhibit 99.1 FORTRESS COVE LIMITED INDEX OF FINANCIAL STATEMENTS Financial Statements Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheet as of December 31, 2023 F-3 Consolidated Statement of Operations and Comprehensive Loss for the Period from November 2, 2023 (Inception) through December 31, 2023 F-4 Consolidated Statement of Changes in Shareholders’ Deficit f

NEW YORK OFFICE ● 7 Penn Plaza ● Suite 830 ● New York, New York ● 10001 Phone 646.442.4845 ● Fax 646.349.5200 ● www.marcumasia.com

Exhibit 16.1 September 9, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by EUDA Health Holdings Limited under Item 16.1 of its Form 6-K dated September 9, 2024. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disagree with other statements of EUDA Health Holding

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Addre

EX-10.1

Exhibit 10.1

EX-10.1

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40678

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address of

EX-10.1

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40678

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40678

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address of

EX-10.1

Exhibit 10.1

EUDA HEALTH HOLDINGS LIMITED Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities

Exhibit 4.1 EUDA HEALTH HOLDINGS LIMITED Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities This Policy provides guidelines to employees, executive officers and directors of, and consultants and contractors to EUDA Health Holdings Limited (the “Company”) with respect to transactions in the Company’s securities. Applicability of Policy This Policy appli

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EUDA HEALTH HOLDINGS LIMITED CLAWBACK POLICY

Exhibit 97 EUDA HEALTH HOLDINGS LIMITED CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of EUDA Health Holdings Limited (formerly known as 8i Acquisition 2 Corp.

DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

Exhibit 2.1 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED General The authorized capital stock of the Company consists of an unlimited number of shares of a single class, each with no par value. No preferred shares are issued or outstanding or authorized by the Company’s Charter. Ordinary Shares The Company’s shareholde

EUDA Health Holdings Limited Completes Acquisition of CK Health Plus Sdn Bhd, Expanding into Direct Selling Holistic Wellness Products in Southeast Asia

Exhibit 99.1 EUDA Health Holdings Limited Completes Acquisition of CK Health Plus Sdn Bhd, Expanding into Direct Selling Holistic Wellness Products in Southeast Asia Singapore, May 08, 2024 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosyst

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40678

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40678

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address of

[remaining of this page is intentionally left blank]

Exhibit 10.1 Share Purchase Agreement BETWEEN THE PERSONS NAMED IN SCHEDULE 1 HERETO (as vendorS) AND EUDA HEALTH HOLDINGS LIMITED (as purchaser) conyers.com TABLE OF CONTENTS 1. INTERPRETATION 3 2. SALE AND PURCHASE 5 3. CONSIDERATION 5 4. conditions precedent 5 5. EARN OUT 6 6. registration rights 6 7. COMPLETION ARRANGEMENTS 7 8. REPRESENTATIONS AND WARRANTIES 8 10. Limitation on LIABILITIES 13

EUDA Health Expands into Direct Selling Holistic Wellness Products with Acquisition of CK Health

Exhibit 99.1 EUDA Health Expands into Direct Selling Holistic Wellness Products with Acquisition of CK Health SINGAPORE, May 6, 2024 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-4067

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-40678 CUSIP NUMBER G3142E105 (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra

FEE SETTLEMENT AGREEMENT

Exhibit 10.2 FEE SETTLEMENT AGREEMENT This Agreement (this “Agreement”), is made and entered into as of April 25, 2024, by and between EUDA Health Holdings LTD., a British Virgin Islands company (the “Company”), and Loeb & Loeb LLP, a California limited liability partnership (“Loeb”). WHEREAS, reference is made to that certain agreement, dated November 16, 2024 (the “Fee Agreement”) by and between

[SIGNATURE PAGE FOLLOWS]

Exhibit 10.1 AGREEMENT This Agreement (this “Agreement”), is made and entered into as of November 16, 2022, by and between 8i Acquisition 2 Corp., a British Virgin Islands company (the “Company”), and Loeb & Loeb LLP, a California limited liability partnership (“Loeb”). WHEREAS, pursuant to the terms of an engagement letter executed on February 11, 2022 (the “Engagement Letter”), the Company engag

EX-10.2

Exhibit 10.2

EX-10.1

Exhibit 10.1

EX-10.3

Exhibit 10.3

EX-10.4

Exhibit 10.4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-4067

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address o

EX-10.1

Exhibit 10.1

CONVERTIBLE PROMISSORY NOTE

Exhibit 10.6 NEITHER THIS NOTE, NOR THE SHARES UNDERLYING THIS NOTE, HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND THE SHARES UNDERLYING THIS NOTE MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE OF THE UNDERLYING SHARES THEREOF UNDER THE SECURITIES ACT OR AN OPINION

EX-10.2

Exhibit 10.2

[SIGNATURE PAGE FOLLOWS]

Exhibit 10.5 AGREEMENT This Agreement (this “Agreement”), is made and entered into as of March 1 5, 2024, by and between EUDA Health Holdings Limited, a British Virgin Islands company (the “Company”), and 8i Enterprises Pte Ltd (“8iEPL”). WHEREAS, pursuant to the terms of a series of loan agreements executed on May 15, 2023, May 18, 2023, May 22, 2023, August 5, 2023, August 29, 2023, September 4,

[SIGNATURE PAGE FOLLOWS]

Exhibit 10.4 AGREEMENT This Agreement (this “Agreement”), is made and entered into as of March 15 , 2024, by and between EUDA Health Holdings Limited, a British Virgin Islands company (the “Company”), and Meng Dong (James) Tan (“Mr. Tan”). WHEREAS, pursuant to the terms of loan agreement dated May 15, 2023 (the “Loan Agreement”), the Company borrowed the sum of US$22,500.00 from Mr. Tan (the “Orig

EX-10.3

Exhibit 10.3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-4067

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address o

EUDA / EUDA Health Holdings Limited / Tan Meng Dong Passive Investment

SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 EUDA HEALTH HOLDINGS LIMITED (Name of Issuer) ORDINARY SHARES, NO PAR VALUE (Title of Class of Securities) G3142E105 (CUSIP Number) DECEMB

AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE

Exhibit 10.1 AMENDMENT NO. 1 TO CONVERTIBLE PROMISSORY NOTE This First Amendment (the “Amendment”) to the convertible promissory note of EUDA Health Holdings Limited, Inc. (the “Company”), dated November 17, 2022 (the “Note”) is made and entered into as of February 29, 2024 by and between the Company and the Holder, Maxim Group LLC (“Maxim”). The Company and Maxim are herein collectively referred

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Addres

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Addres

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address

CONVERTIBLE LOAN AGREEMENT

Exhibit 10.1 THIS CONVERTIBLE LOAN AGREEMENT is made the 16th day of January 2024. Between:- (1) Gilandi Limited, a company incorporated in the British Virgin Islands and having its registered office at Suite 30C, 30/F Morrision Plaza, 5-9 Morrison hill road, Wan Chai Hong Kong island, Hong kong (“the Lender”); and (2) Euda Health Holdings Limited, a company incorporated in the British Virgin Isla

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

Exhibit 99.2 EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements After receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency Singapore. January 16, 2024 (Globe Newswire) - As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Nasdaq on January 9, 2024 indicating

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address

EUDA Health Holdings Limited Has Received Nasdaq Notification Regarding Minimum Market Value Deficiency

Exhibit 99.1 EUDA Health Holdings Limited Has Received Nasdaq Notification Regarding Minimum Market Value Deficiency Singapore. January 16, 2024 (Globe Newswire) - EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on January 9, 2024 indicating that the Company had failed

OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022

Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022 In this report, as used herein, and unless the context suggests otherwise, the terms “EUDA,” “Company,” “we,” “us” or “our” refer to the combined business of Euda Health Holdings Limited and its subsidiaries a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Addres

EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

Exhibit 99.1 EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2023 December 31, 2022 (Unaudited) ASSETS CURRENT ASSETS Cash $ 320,486 $ 143,024 Restricted cash - 641,461 Accounts receivable, net 880,226 1,851,503 Other receivables 20,261 7,467 Due from related parties - 267,863 Prepaid expenses and other current assets 250,941 222,633 Forward p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Addre

EUDA Health Holdings Limited 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 +65 6268 6821 22,439,888 Ordinary Shares 4,458,625 Ordinary Shares Issuable Upon the Exercise of Warrants 1,120,299 Ordinary Shares Issuable upon Conversion of $2,413,

Filed pursuant to Rule 424(b)(3) Registration No. 333-268994 EUDA Health Holdings Limited 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 +65 6268 6821 22,439,888 Ordinary Shares 4,458,625 Ordinary Shares Issuable Upon the Exercise of Warrants 1,120,299 Ordinary Shares Issuable upon Conversion of $2,413,125 principal amount of Convertible Notes 292,250 Warrants to Purchase Ordinary Shares Th

EUDA HEALTH HOLDINGS LIMITED 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151

EUDA HEALTH HOLDINGS LIMITED 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 September 19, 2023 VIA EDGAR Mr.

As filed with the Securities and Exchange Commission on September 8, 2023

As filed with the Securities and Exchange Commission on September 8, 2023 Registration No.

Calculation of Filing Fee Tables FORM F-1 (Form Type) EUDA HEALTH HOLDINGS LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) EUDA HEALTH HOLDINGS LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price (1)(2) Amount of Registration Fee Fees Previously Paid Equity Warrants to purchase ordinary shares Rule 457(a); Rule 457(i) 292,250 $ 11.

345 Park Avenue

345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 September 8, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Conlon Danberg and Jane Park Re: EUDA Health Holdings Limited Amendment No. 1 to Registration Statement on Form

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-406

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address

Filing Fee Exhibit

Exhibit 107 Calculation of Filing Fee Tables FORM F-1 (Form Type) EUDA HEALTH HOLDINGS LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price (1)(2) Amount of Registration Fee Fees Previously Paid Equity Warrants to purchase ordinary shares Rule 457(a); Rule 457(i) 292,250 $ 11.

As filed with the Securities and Exchange Commission on August 4, 2023

As filed with the Securities and Exchange Commission on August 4, 2023 Registration No.

345 Park Avenue

345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 August 4, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attn: Jane Park Re: EUDA Health Holdings Limited Registration Statement on Form S-1 Filed December 23, 2022 File No. 333

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-40678

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40678 EUDA HEALTH HOLDINGS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-40678

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-40678 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address of

Description of Registered Securities.

Exhibit 4.5 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED General The authorized capital stock of the Company consists of an unlimited number of shares of a single class, each with no par value. No preferred shares are issued or outstanding or authorized by the Company’s Charter. Ordinary Shares The Company’s shareholde

List of Subsidiaries

Exhibit 21.1 Subsidiaries of EUDA Health Holdings Limited EUDA Doctor Private Limited, A Singapore company EUDA Health Limited, A British Virgin Islands company EUDA Private Limited, A Singapore company Kent Ridge Health Limited, A British Virgin Islands company Kent Ridge Healthcare Singapore Pte. Ltd., A Singapore company Kent Ridge Hill Private Limited, A Singapore company KR Digital Pte. Ltd.,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40678 EUDA HEALTH HOLDINGS LIMI

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction (Commission (I.R.S.

Amendment to Prepaid Forward Agreement dated June 8, 2023 (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on June 9, 2023)

Exhibit 10.3

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction (Commission (I.R.S.

Supplemental Agreement with Kelvin Chen, dated June 6, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on June 9, 2023)

EX-10.1 2 ex10-1.htm Exhibit 10.1

Amendment to Prepaid Forward Agreement dated June 8, 2023 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on June 9, 2023)

Exhibit 10.2

Settlement Agreement with Kelvin Chen, dated May 16, 2023

Exhibit 10.5

Settlement Agreement with 8i Holdings 2 Pte Ltd., dated May 16, 2023

Exhibit 10.2

Settlement Agreement with Menora Capital Pte Ltd, dated May 16, 2023

Exhibit 10.4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 EUDA Health Holdings

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction (Commission (I.R.S.

Form of Registration Rights Agreement, dated May 16, 2023

Exhibit 10.6 Registration Rights Agreement This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], 2023, between EUDA Health Holdings Limited, a British Virgin Islands business company (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the

VGG3142E1051 / EUDA HEALTH HOLDINGS LTD / Tan Meng Dong Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under the Securities Exchange Act of 1934 EUDA Health Holdings Limited (Name of Company) Ordinary Shares, no par value (Title of Class of Securities) G3142E105 (CUSIP) Wei Wen Kelvin Chen Chief Executive Officer c/o 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 Tel: +65-6268 6821 (Name,

Settlement Agreement with Shine Link Limited, dated May 16, 2023

Exhibit 10.3

Settlement Agreement with Mr. Meng Dong (James) Tan, dated May 16, 2023

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 EUDA Health Holdings

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction (Commission (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 EUDA Health Holdings

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of  incorporation) (

EUDA Health Holdings Limited Announces Receipt of Nasdaq Listing Delinquency Letter

Exhibit 99.1 EUDA Health Holdings Limited Announces Receipt of Nasdaq Listing Delinquency Letter Singapore, May 19, 2023 – EUDA Health Holdings Limited (the “Company” or “EUDA”) (NASDAQ: EUDA, EUDAW), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, announced today that it received a delinquency notification letter (“Notice

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-40678 CUSIP NUMBER G3142E105 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2023 EUDA Health Holdings

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2023 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction (Commission (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 (May 11, 2023) EUDA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 (May 11, 2023) EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of  i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 (April 5, 2023) EU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 (April 5, 2023) EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of

EUDA Health Holdings Limited Announces Receipt of Nasdaq Listing Delinquency Letter

Exhibit 99.1 EUDA Health Holdings Limited Announces Receipt of Nasdaq Listing Delinquency Letter Singapore, April 10, 2023 – EUDA Health Holdings Limited (the “Company” or “EUDA”) (NASDAQ: EUDA, EUDAW), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, announced today that it received a delinquency notification letter (“Noti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

Acceptance Letter of Mr. Lew Chern Yong (Eric), effective March 12, 2023.

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 (March 12, 2023) E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 (March 12, 2023) EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction o

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 (March 1, 2023) EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 (February 23, 2023) EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction

EUDA HEALTH HOLDINGS LIMITED Board of Director Officer Letter

Exhibit 99.1 EUDA HEALTH HOLDINGS LIMITED Board of Director Officer Letter February 15, 2023 Mr. Chee Hyong Leonard Chia On behalf of the board of the directors (the “Board”) of EUDA Health Holdings Limited, a British Virgin Islands business company (the “Company”), I am pleased to invite you to join the Board of Directors. You will serve as a Class II director from the date of acceptance indicate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 (February 15, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 (February 15, 2023) EUDA Health Holdings Limited (Exact name of registrant as specified in its charter) British Virgin Islands 001-40678 n/a (State or other jurisdic

EUDA / Euda Health Holdings Limited / Ayrton Capital LLC Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* EUDA HEALTH HOLDINGS LIMITED (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) G3142E105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1)

EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Ordinary Shares, no par value, of EUDA Health Holdings Limited, beneficially owned by them, together with any or all amendments thereto, when and if approp

EUDA / Euda Health Holdings Limited / Hudson Bay Capital Management LP - EUDA 13GA Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* EUDA Health Holdings Limited (f/k/a 8i Acquisition 2 Corp.) (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) G3142E105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 EUDA Health Hold

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2023 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of  incorporatio

Form of Warrant Agreement between American Stock Transfer & Trust Company, LLC and 8i Acquisition 2 Corp.

Exhibit 4.2 FORM OF WARRANT AGREEMENT BETWEEN American Stock Transfer & Trust Company, LLC AND THE REGISTRANT WARRANT AGREEMENT This Warrant Agreement (“Warrant Agreement”) is made as of [*], 2021, by and between 8i Acquisition 2 Corp., a British Virgin Islands company (the “Company”), and American Stock Transfer & Trust Company, LLC (the “Warrant Agent”). WHEREAS, the Company is engaged in a publ

Amendment No. 2 to Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated June 10, 2022

Exhibit 2.3 AMENDMENT NO. 2 TO THE SHARE PURCHASE AGREEMENT This Amendment No. 2 to the Share Purchase Agreement (this “Amendment”) is made as of June 10, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the “Company”), Watermark Developments Limited, a British Virgin Islands business company (“Seller”), and 8i Acquisition 2 Corp., a British Virgin Islands busines

List of Subsidiaries

Exhibit 21.1 Subsidiaries of EUDA Health Holdings Limited EUDA Doctor Private Limited, A Singapore company EUDA Health Limited, A British Virgin Islands company EUDA Private Limited, A Singapore company Kent Ridge Health Limited, A British Virgin Islands company Kent Ridge Healthcare Singapore Pte. Ltd., A Singapore company Kent Ridge Hill Private Limited, A Singapore company KR Digital Pte. Ltd.,

Specimen Warrant Certificate

Exhibit 4.1 SPECIMEN WARRANT CERTIFICATE NUMBER WA- [ ] WARRANTS (THIS WARRANT WILL BE VOID IF NOT EXERCISED PRIOR TO 5:00 P.M. NEW YORK CITY TIME, FIVE YEARS FROM THE CLOSING DATE OF THE COMPANY’S INITIAL BUSINESS COMBINATION) 8i ACQUISITION 2 CORP. CUSIP WARRANT THIS WARRANT CERTIFIES THAT, for value received , or registered agents, is the registered holder of a Warrant or Warrants (the “Warrant

Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated April 11, 2022

EX-2.1 2 ex2-1.htm Exhibit 2.1 SHARE PURCHASE AGREEMENT by and among EUDA HEALTH LIMITED, WATERMARK DEVELOPMENTS LIMITED, 8I ACQUISITION 2 CORP., and Kwong Yeow Liew Dated as of April 11, 2022 TABLE OF CONTENTS Page Article I Purchase 2 1.1 Purchase and Sale of Shares 2 1.2 Purchase Price 2 1.3 Payment of Expenses 2 1.4 Indemnification Escrow Shares 2 1.5 Closing Statements 2 1.6 Earn-Out 3 Articl

Amendment No. 3 to Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated September 7, 2022

EX-2.1 5 ex2-4.htm Exhibit 2.4 AMENDMENT NO. 3 TO THE SHARE PURCHASE AGREEMENT This Amendment No. 3 to the Share Purchase Agreement (this “Amendment”) is made as of September 7, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the “Company”), Watermark Developments Limited, a British Virgin Islands business company (“Seller”), and 8i Acquisition 2 Corp., a British

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 Registration Statement The Securities Act of 1933 EUDA HEALTH HOLDINGS LIMITED (Exact Name of Registrant as Specified in its Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 Registration Statement Under The Securities Act of 1933 EUDA HEALTH HOLDINGS LIMITED (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 8000 n/a (State or other jurisdiction of  incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identific

Form of Amended and Restated Registration Rights Agreement

Exhibit 10.1 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), effective as of the [●] day of [●], 2022 (the “Effective Date”), is made and entered into by and among (i) 8i Acquisition 2 Corp., a British Virgin Islands company (the “Company”), (ii) each of the undersigned parties that are Pre-BC Investors (as defined belo

Form of First Amendment to Amended and Restated Registration Rights Agreement

Exhibit 10.2 First Amendment to Amended and Restated Registration Rights Agreement This First Amendment to the Amended and Restated Registration Rights Agreement (this “Amendment”), dated as of November 30, 2022, is made and entered into by and among EUDA Health Holdings Limited (formerly known as 8i Acquisition 2 Corp.), a British Virgin Islands business company (the “Company”), and each of the u

Form of Indemnification Agreement

Exhibit 10.3 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of November 17, 2022, by and between EUDA Health Holdings Limited, a British Virgin Islands business company (the “Company”), and a member of the board of directors and/or officer of the Company, as applicable (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between

Letter from UHY LLP to the SEC, dated November 23, 2022

EX-16.1 16 ex16-1.htm Exhibit 16.1 1185 Avenue of the Americas, 38th Floor New York, NY 10036-2603 Phone 212-381-4800 Fax 212-381-4811 Web www.uhy-us.com November 23, 2022 Office of the Chief Accountant Securities and Exchange Commission 460 Fifth Street N. W. Washington, DC 20549 Re: EUDA Health Holdings Limited Ladies and Gentlemen: We have read Item 4.01 of Form 8-K filed with the U.S. Securiti

Filing Fee Exhibit

EX-FILING FEES 20 ex107.htm Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) EUDA HEALTH HOLDINGS LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Security Maximum Aggregate Offeri

Form of Lock-up Agreement

Exhibit 10.4 LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (this “Agreement”) is dated as of , 2022 by and between Watermark Developments Limited, a British Virgin Islands Company (the “Holder”) and 8i Acquisition 2 Corp., a British Virgin Islands company (the “Parent”). A. Parent, the Holder, Euda Health Limited, British Virgin Islands company (the “Company”) and , entered into a Stock Purchase Agreem

Form of Seller Release

Exhibit 10.5 SELLER RELEASE This Seller Release (this “Release”) is dated as of this day of April, 2022, by and among Watermark Developments Limited, a British Virgin Islands corporation (the “Releasing Party”), in its capacity as the sole stockholder of Euda Health Limited, a British Virgin Islands corporation (the “Company”), the Company, and 8i Acquisition 2 Corp., a British Virgin Islands corp

Amendment No. 1 to Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated May 30, 2022

Exhibit 2.2 AMENDMENT NO. 1 TO THE SHARE PURCHASE AGREEMENT This Amendment No. 1 to the Share Purchase Agreement (this “Amendment”) is made as of May 30, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the “Company”), Watermark Developments Limited, a British Virgin Islands business company (“Seller”), and 8i Acquisition 2 Corp., a British Virgin Islands business

Amended and Restated Memorandum and Articles of Association of EUDA Health Holdings Limited

Exhibit 3.1

Specimen Ordinary Share Certificate of EUDA Health Holdings Limited

Exhibit 4.3

VGG2956R1038 / 8i ACQUISITION 2 Corp. / Karpus Management, Inc. - KARPUS INVESTMENT MGT / 8I ACQUISITION 2 - SCHEDULE 13G/A(#1) Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * 8i Acquisition 2 Corp. (Name of Issuer) Common (Title of Class of Securities) G2956R103 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Sched

EUDA / Euda Health Holdings Limited / Tan Meng Dong Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 EUDA Health Holdings Limited (Name of Company) Ordinary Shares, no par value (Title of Class of Securities) G3142E105 (CUSIP) Wei Wen Kelvin Chen Chief Executive Officer c/o 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 Tel: +65-6268 6821 (Name, Address and Telepho

EUDA / Euda Health Holdings Limited / Watermark Developments Ltd Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 EUDA Health Holdings Limited (Name of Company) Ordinary Shares, no par value (Title of Class of Securities) G3142E105 (CUSIP) Wei Wen Kelvin Chen Chief Executive Officer 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 Tel: +65-6268 6821 (Name, Address and Telephone N

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information present the combination of the financial information of 8i and EUDA adjusted to give effect to the Business Combination. The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regu

Amended and Restated Memorandum and Articles of Association of EUDA Health Holdings Limited

Exhibit 3.1

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF EUDA

Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF EUDA You should read the following discussion and analysis of Euda Health Limited (?EUDA?)?s financial condition and results of operations in conjunction with its audited condensed consolidated financial statements and the notes related thereto which are included elsewhere in the Current Report on

Euda Health Limited and Subsidiaries Index to Unaudited Condensed Consolidated Financial Statements

EX-99.1 7 ex99-1.htm Exhibit 99.1 Euda Health Limited and Subsidiaries Index to Unaudited Condensed Consolidated Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and December 31, 2021 (Audited) 2 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Nine Months Ended September 30, 2022 and 2021 3 Unaudited C

Form of Indemnification Agreement

Exhibit 10.2 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of November 17, 2022, by and between EUDA Health Holdings Limited, a British Virgin Islands business company (the ?Company?), and a member of the board of directors and/or officer of the Company, as applicable (?Indemnitee?). This Agreement supersedes and replaces any and all previous Agreements between

List of Subsidiaries

Exhibit 21.1 Subsidiaries of EUDA Health Holdings Limited EUDA Doctor Private Limited, A Singapore company EUDA Health Limited, A British Virgin Islands company EUDA Private Limited, A Singapore company Kent Ridge Health Limited, A British Virgin Islands company Kent Ridge Healthcare Singapore Pte. Ltd., A Singapore company Kent Ridge Hill Private Limited, A Singapore company KR Digital Pte. Ltd.,

Change in Shell Company Status, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 EUDA Health Holdings Limited (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of ?incorporati

Specimen Ordinary Share Certificate of EUDA Health Holdings Limited

Exhibit 4.3

Letter from UHY LLP to the SEC, dated November 23, 2022

Exhibit 16.1 1185 Avenue of the Americas, 38th Floor New York, NY 10036-2603 Phone 212-381-4800 Fax 212-381-4811 Web www.uhy-us.com November 23, 2022 Office of the Chief Accountant Securities and Exchange Commission 460 Fifth Street N. W. Washington, DC 20549 Re: EUDA Health Holdings Limited Ladies and Gentlemen: We have read Item 4.01 of Form 8-K filed with the U.S. Securities and Exchange Commis

EUDA / Euda Health Holdings Limited / Ayrton Capital LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

8i Acquisition 2 Corp. and EUDA Health Limited Complete Business Combination

Exhibit 99.4 8i Acquisition 2 Corp. and EUDA Health Limited Complete Business Combination Singapore, November 17, 2022 ? 8i Acquisition 2 Corp. (the ?Company? or ?LAX?) (NASDAQ: LAX), a publicly traded special purpose acquisition company, today announced the completion of its business combination (the ?Business Combination?) with EUDA Health Limited (?EUDA Health?), a Singapore-based digital healt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended October 31, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended October 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40678 EUDA HEALTH HOLDING

Prepaid Forward Agreement, dated November 13, 2022

Exhibit 10.1 Date: November 13, 2022 To: 8i Acquisition 2 Corp., a British Virgin Islands business company (“8i”) and EUDA Health Limited, a British Virgin Islands business company (the “EUDA”). Address: 6 Eu Tong Sen Street #08-13 Singapore 059817 From: Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (“Seller”) Re: OTC Equity Prepaid Forward Transaction The purpose of this agree

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of ?incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2022 8i Acquisition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of  incorporation) (C

Prepaid Forward Agreement, dated November 13, 2022

Exhibit 10.1 Date: November 13, 2022 To: 8i Acquisition 2 Corp., a British Virgin Islands business company (?8i?) and EUDA Health Limited, a British Virgin Islands business company (the ?EUDA?). Address: 6 Eu Tong Sen Street #08-13 Singapore 059817 From: Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (?Seller?) Re: OTC Equity Prepaid Forward Transaction The purpose of this agree

Prepaid Forward Agreement, dated November 9, 2022

Exhibit 10.1 Date: November 9, 2022 To: 8i Acquisition 2 Corp., a British Virgin Islands business company (?8i?) and EUDA Health Limited, a British Virgin Islands business company (the ?EUDA?). Address: 6 Eu Tong Sen Street #08-13 Singapore 059817 From: HB Strategies LLC (?Seller?) Re: OTC Equity Prepaid Forward Transaction The purpose of this agreement (this ?Confirmation?) is to confirm the term

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 2) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 2) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 8i Acquisition 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of ?incorporation) (Co

Termination Agreement, dated November 9, 2022

Exhibit 10.2 8I ACQUISITION 2 CORP. 6 Eu Tong Sen Street #08-13 Singapore 059817 Tel: +65-6788 0388 November 9, 2022 VIA E-MAIL Greentree Financial Group, Inc. Attn: Robert C. Cottone 7951 S.W. 6TH Street, Suite 216 Plantation, FL 33324 Email: [email protected] Re: Agreement By and Among Greentree Financial Group, Inc., a Florida corporation (?Investor?) and 8i Acquisition 2 Corp., a Br

Termination Agreement, dated November 9, 2022

Exhibit 10.2 8I ACQUISITION 2 CORP. 6 Eu Tong Sen Street #08-13 Singapore 059817 Tel: +65-6788 0388 November 9, 2022 VIA E-MAIL Greentree Financial Group, Inc. Attn: Robert C. Cottone 7951 S.W. 6TH Street, Suite 216 Plantation, FL 33324 Email: [email protected] Re: Agreement By and Among Greentree Financial Group, Inc., a Florida corporation (?Investor?) and 8i Acquisition 2 Corp., a Br

Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of ?incorporation) (C

Prepaid Forward Agreement, dated November 9, 2022

Exhibit 10.1 Date: November 9, 2022 To: 8i Acquisition 2 Corp., a British Virgin Islands business company (?8i?) and EUDA Health Limited, a British Virgin Islands business company (the ?EUDA?). Address: 6 Eu Tong Sen Street #08-13 Singapore 059817 From: HB Strategies LLC (?Seller?) Re: OTC Equity Prepaid Forward Transaction The purpose of this agreement (this ?Confirmation?) is to confirm the term

8i Acquisition 2 Corp. Announces Approval of Business Combination and Ability of Shareholders to Withdraw Ordinary Shares Tendered for Redemption

EX-99.1 2 ex99-1.htm Exhibit 99.1 8i Acquisition 2 Corp. Announces Approval of Business Combination and Ability of Shareholders to Withdraw Ordinary Shares Tendered for Redemption Singapore, November 10, 2022 /PRNewswire/ — 8i Acquisition 2 Corp. (NASDAQ: LAX, the “Company”), a special purpose acquisition company, announced today that all proposals presented to shareholders at the special meeting

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of ?incorporation) (Co

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of ?incorporation) (Co

Forward Purchase Agreement, dated November 1, 2022

Exhibit 10.1 FORWARD SHARE PURCHASE AGREEMENT This Forward Share Purchase Agreement (this ?Agreement?) is entered into as of November 1, 2022 by and among (i) 8i Acquisition 2 Corp., a British Virgin Islands business company (the ?Company?) and (ii) Greentree Financial Group, Inc., a Florida corporation (?Investor?). Each of the Company and Investor is individually referred to herein as a ?Party?

Wavier Agreement, dated November 7, 2022

Exhibit 10.2 Waiver Reference is made to that certain Share Purchase Agreement dated as of April 11, 2022, and amended as of May 30, 2022, June 10, 2022, and September 7, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the ?Company?), Watermark Developments Limited, a British Virgin Islands business company (?Seller?), 8i Acquisition 2 Corp., a British Virgin Isl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 8i Acquisition 2

DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdicti

Research Report, dated August 30, 2022

Exhibit 99.1

Research Report, dated August 30, 2022

Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of ?incorporation) (Com

Amendment No. 3 to Share Purchase Agreement, dated as of September 7, 2022, by and among EUDA Health Limited, Watermark Developments Limited, 8i Acquisition 2 Corp., and Kwong Yeow Liew.

EX-2.1 2 ex2-1.htm Exhibit 2.1 AMENDMENT NO. 3 TO THE SHARE PURCHASE AGREEMENT This Amendment No. 3 to the Share Purchase Agreement (this “Amendment”) is made as of September 7, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the “Company”), Watermark Developments Limited, a British Virgin Islands business company (“Seller”), and 8i Acquisition 2 Corp., a British

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 8i Acquisition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of ?incorporation) (C

345 Park Avenue

345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 September 8, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jordan Nimitz Re: 8i Acquisition 2 Corp. Amendment No. 2 to Preliminary Proxy Statement on Schedule 14A Submitted August 18, 2022 CIK

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 3 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 3 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini

Amendment No. 3 to Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated September 7, 2022 (incorporated by reference to Exhibit 2.1 to 8i Acquisition 2 Corp. Current Report on Form 8-K filed September 8, 2022).

Exhibit 2.1 AMENDMENT NO. 3 TO THE SHARE PURCHASE AGREEMENT This Amendment No. 3 to the Share Purchase Agreement (this ?Amendment?) is made as of September 7, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the ?Company?), Watermark Developments Limited, a British Virgin Islands business company (?Seller?), and 8i Acquisition 2 Corp., a British Virgin Islands bus

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40678 n/a (State or other jurisdiction of ?incorporation) (C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2022 ☐ TRANSITION REPORT UNDER SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40462 8i ACQUISITION 2 CORP. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 2 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 2 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini

345 Park Avenue

345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 August 18, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jordan Nimitz Re: 8i Acquisition 2 Corp. Amendment No. 1 to Preliminary Proxy Statement on Schedule 14A Submitted July 25, 2022 CIK No.

Promissory Note dated August 16, 2022

EX-10.1 2 ex10-1.htm Exhibit 10.1

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of ?incorporation) (Com

345 Park Avenue

345 Park Avenue New York, NY 10154-1895 Direct 212.407.4000 Main 212.407.4000 Fax 212.407.4990 July 25, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jordan Nimitz Re: 8i Acquisition 2 Corp. Preliminary Proxy Statement on Schedule 14A Submitted June 15, 2022 CIK No. 0001847846 Dear Ms. N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 1 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A AMENDMENT NO. 1 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini

Calculation of Filing Fee Tables 8i Acquisition 2 Corp. FORM PREM14A (Form Type) (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 8i Acquisition 2 Corp. FORM PREM14A (Form Type) (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registrati

Executive Summary of Investor Presentation dated July 2022

EX-99.2 3 ex99-2.htm Exhibit 99.2

Investor Presentation dated July 2022

EX-99.1 2 ex99-1.htm Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 8i Acquisition 2 Cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of ?incorporation) (Commis

Executive Summary of Investor Presentation dated July 2022

Exhibit 99.2

Investor Presentation dated July 2022

Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of ?incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Calculation of Filing Fee Tables 8i Acquisition 2 Corp. FORM PREM14A (Form Type) (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

EX-FILING FEES 2 ex107.htm Exhibit 107 Calculation of Filing Fee Tables 8i Acquisition 2 Corp. FORM PREM14A (Form Type) (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fe

Amendment No. 2 to Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated June 10, 2022 (incorporated by reference to Exhibit 2.1 to 8i Acquisition 2 Corp. Current Report on Form 8-K filed June 10, 2022).

Exhibit 2.1 AMENDMENT NO. 2 TO THE SHARE PURCHASE AGREEMENT This Amendment No. 2 to the Share Purchase Agreement (this ?Amendment?) is made as of June 10, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the ?Company?), Watermark Developments Limited, a British Virgin Islands business company (?Seller?), and 8i Acquisition 2 Corp., a British Virgin Islands busines

Executive Summary of Investor Presentation dated June 10, 2022

Exhibit 99.3 Notes: ? Forecasts are based on Base scenario which projects existing services to further expand in Singapore. The existing services are Medical Urgent Care, Property Management Services and Euda Society (Doctor?s Insurance). ? The Property Management Service covers the management of properties such as condominiums and shopping malls. Categorized under Home Care Service line from 2023

Press Release issued by LAX and EUDA Health, dated June 10, 2022

EX-99.1 3 ex99-1.htm Exhibit 99.1 8i Acquisition 2 Corp. and EUDA Health Limited Announce Amendment to Share Purchase Agreement Singapore, June 10, 2022 – 8i Acquisition 2 Corp. (the “Company” or “LAX”) (NASDAQ: LAX), a publicly traded special purpose acquisition company, and EUDA Health Limited (“EUDA Health”), a Singapore-based digital health platform that aims to make healthcare more affordable

Executive Summary of Investor Presentation dated June 10, 2022

Exhibit 99.3 Notes: ? Forecasts are based on Base scenario which projects existing services to further expand in Singapore. The existing services are Medical Urgent Care, Property Management Services and Euda Society (Doctor?s Insurance). ? The Property Management Service covers the management of properties such as condominiums and shopping malls. Categorized under Home Care Service line from 2023

Amendment No. 2 to Share Purchase Agreement, dated as of June 10, 2022, by and among Euda Health Limited, Watermark Developments Limited, 8i Acquisition 2 Corp., and Kwong Yeow Liew.

Exhibit 2.1 AMENDMENT NO. 2 TO THE SHARE PURCHASE AGREEMENT This Amendment No. 2 to the Share Purchase Agreement (this ?Amendment?) is made as of June 10, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the ?Company?), Watermark Developments Limited, a British Virgin Islands business company (?Seller?), and 8i Acquisition 2 Corp., a British Virgin Islands busines

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 8i Acquisition 2 Co

DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction

Investor Presentation dated June 10, 2022

Exhibit 99.2

Investor Presentation dated June 10, 2022

Exhibit 99.2

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of ?incorporation) (Commi

8i Acquisition 2 Corp. and EUDA Health Limited Announce Amendment to Share Purchase Agreement

Exhibit 99.1 8i Acquisition 2 Corp. and EUDA Health Limited Announce Amendment to Share Purchase Agreement Singapore, June 10, 2022 ? 8i Acquisition 2 Corp. (the ?Company? or ?LAX?) (NASDAQ: LAX), a publicly traded special purpose acquisition company, and EUDA Health Limited (?EUDA Health?), a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and imp

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of ?incorporation) (Commis

Press Release issued by LAX and EUDA Health, dated May 31, 2022

Exhibit 99.1 8i Acquisition 2 Corp. and EUDA Health Limited Announce Extension of Due Diligence Review Period Singapore, May 31, 2022 ? 8i Acquisition 2 Corp. (the ?Company? or ?LAX?) (NASDAQ: LAX), a publicly traded special purpose acquisition company, and EUDA Health Limited, a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patie

Amendment No. 1 to Share Purchase Agreement, dated as of May 30, 2022, by and among Euda Health Limited, Watermark Developments Limited, 8i Acquisition 2 Corp., and Kwong Yeow Liew.

Exhibit 2.1 AMENDMENT NO. 1 TO THE SHARE PURCHASE AGREEMENT This Amendment No. 1 to the Share Purchase Agreement (this ?Amendment?) is made as of May 30, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the ?Company?), Watermark Developments Limited, a British Virgin Islands business company (?Seller?), and 8i Acquisition 2 Corp., a British Virgin Islands business

8i Acquisition 2 Corp. and EUDA Health Limited Announce Extension of Due Diligence Review Period

Exhibit 99.1 8i Acquisition 2 Corp. and EUDA Health Limited Announce Extension of Due Diligence Review Period Singapore, May 31, 2022 ? 8i Acquisition 2 Corp. (the ?Company? or ?LAX?) (NASDAQ: LAX), a publicly traded special purpose acquisition company, and EUDA Health Limited, a Singapore-based digital health platform that aims to make healthcare more affordable, accessible, and improve the patie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2022 8i Acquisition 2 Cor

DEFA14A 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of  

Amendment No. 1 to Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated May 30, 2022 (incorporated by reference to Exhibit 2.1 to 8i Acquisition 2 Corp. Current Report on Form 8-K filed June 1, 2022).

Exhibit 2.1 AMENDMENT NO. 1 TO THE SHARE PURCHASE AGREEMENT This Amendment No. 1 to the Share Purchase Agreement (this ?Amendment?) is made as of May 30, 2022, by and among Euda Health Limited, a British Virgin Islands business company (the ?Company?), Watermark Developments Limited, a British Virgin Islands business company (?Seller?), and 8i Acquisition 2 Corp., a British Virgin Islands business

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended April 30, 2022 ☐ TRANSITION REPORT PURSUANT T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended April 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40462 8i ACQUISITION 2 CORP

Form of Lock-Up Agreement

Exhibit 10.1 LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (this ?Agreement?) is dated as of , 2022 by and between Watermark Developments Limited, a British Virgin Islands Company (the ?Holder?) and 8i Acquisition 2 Corp., a British Virgin Islands company (the ?Parent?). A. Parent, the Holder, Euda Health Limited, British Virgin Islands company (the ?Company?) and , entered into a Stock Purchase Agreem

Executive Summary of Investor Presentation dated April 12, 2022

Exhibit 99.3

Investor Presentation dated April 12, 2022

Exhibit 99.2

Share Purchase Agreement between 8i Acquisition 2 Corp., EUDA Health Limited, Watermark Developments Limited, and Kwong Yeow Liew dated April 11, 2022 (incorporated by reference to Exhibit 2.1 to 8i Acquisition 2 Corp. Current Report on Form 8-K filed April 12, 2022).

Exhibit 2.1 SHARE PURCHASE AGREEMENT by and among EUDA HEALTH LIMITED, WATERMARK DEVELOPMENTS LIMITED, 8I ACQUISITION 2 CORP., and Kwong Yeow Liew Dated as of April 11, 2022 TABLE OF CONTENTS Page Article I Purchase 2 1.1 Purchase and Sale of Shares 2 1.2 Purchase Price 2 1.3 Payment of Expenses 2 1.4 Indemnification Escrow Shares 2 1.5 Closing Statements 2 1.6 Earn-Out 3 Article II The Closing 5

Share Purchase Agreement, dated as of April 11, 2022, by and among Euda Health Limited, Watermark Developments Limited, 8i Acquisition 2 Corp., and Kwong Yeow Liew.

Exhibit 2.1 SHARE PURCHASE AGREEMENT by and among EUDA HEALTH LIMITED, WATERMARK DEVELOPMENTS LIMITED, 8I ACQUISITION 2 CORP., and Kwong Yeow Liew Dated as of April 11, 2022 TABLE OF CONTENTS Page Article I Purchase 2 1.1 Purchase and Sale of Shares 2 1.2 Purchase Price 2 1.3 Payment of Expenses 2 1.4 Indemnification Escrow Shares 2 1.5 Closing Statements 2 1.6 Earn-Out 3 Article II The Closing 5

Form of Lock-Up Agreement

EX-10.1 3 ex10-1.htm Exhibit 10.1 LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (this “Agreement”) is dated as of , 2022 by and between Watermark Developments Limited, a British Virgin Islands Company (the “Holder”) and 8i Acquisition 2 Corp., a British Virgin Islands company (the “Parent”). A. Parent, the Holder, Euda Health Limited, British Virgin Islands company (the “Company”) and , entered into a

Investor Presentation dated April 12, 2022

Exhibit 99.2

Form of Seller Release

EX-10.3 5 ex10-3.htm Exhibit 10.3 SELLER RELEASE This Seller Release (this “Release”) is dated as of this day of April, 2022, by and among Watermark Developments Limited, a British Virgin Islands corporation (the “Releasing Party”), in its capacity as the sole stockholder of Euda Health Limited, a British Virgin Islands corporation (the “Company”), the Company, and 8i Acquisition 2 Corp., a Britis

Form of Seller Release

Exhibit 10.3 SELLER RELEASE This Seller Release (this ?Release?) is dated as of this day of April, 2022, by and among Watermark Developments Limited, a British Virgin Islands corporation (the ?Releasing Party?), in its capacity as the sole stockholder of Euda Health Limited, a British Virgin Islands corporation (the ?Company?), the Company, and 8i Acquisition 2 Corp., a British Virgin Islands corp

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 8i Acquisition 2 C

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of ?incorporation) (Comm

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2022 8i Acquisition 2 Corp. (Exact Name of Registrant as Specified in its Charter) British Virgin Islands 001-40462 n/a (State or other jurisdiction of ?incorporation) (Comm

8i Acquisition 2 Corp. to Combine with EUDA Health Limited to Bring a Leading Digital Health Platform Servicing Southeast Asia to the Public Market

Exhibit 99.1 8i Acquisition 2 Corp. to Combine with EUDA Health Limited to Bring a Leading Digital Health Platform Servicing Southeast Asia to the Public Market ? EUDA Health is disrupting the multi-trillion-dollar Southeast Asia healthcare industry with its proprietary unified AI platform that makes healthcare affordable, accessible, and personalized across Southeast Asia ? one of the fastest gro

Form of Amended and Restated Registration Rights Agreement.

Exhibit 10.2 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), effective as of the [?] day of [?], 2022 (the ?Effective Date?), is made and entered into by and among (i) 8i Acquisition 2 Corp., a British Virgin Islands company (the ?Company?), (ii) each of the undersigned parties that are Pre-BC Investors (as defined belo

Form of Amended and Restated Registration Rights Agreement.

EX-10.2 4 ex10-2.htm Exhibit 10.2 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), effective as of the [●] day of [●], 2022 (the “Effective Date”), is made and entered into by and among (i) 8i Acquisition 2 Corp., a British Virgin Islands company (the “Company”), (ii) each of the undersigned parties that are Pre-BC Inves

8i Acquisition 2 Corp. to Combine with EUDA Health Limited to Bring a Leading Digital Health Platform Servicing Southeast Asia to the Public Market

Exhibit 99.1 8i Acquisition 2 Corp. to Combine with EUDA Health Limited to Bring a Leading Digital Health Platform Servicing Southeast Asia to the Public Market ? EUDA Health is disrupting the multi-trillion-dollar Southeast Asia healthcare industry with its proprietary unified AI platform that makes healthcare affordable, accessible, and personalized across Southeast Asia ? one of the fastest gro

Executive Summary of Investor Presentation dated April 12, 2022

EX-99.3 8 ex99-3.htm Exhibit 99.3

LAXXU / 8i Acquisition 2 Corp. Unit / Feis Lawrence Michael - SCHEDULE 13G Passive Investment

Schedule 13G OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended January 31, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended January 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40462 8i ACQUISITION 2 CO

LAXXU / 8i Acquisition 2 Corp. Unit / MIZUHO FINANCIAL GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 d295864dsc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 8i Acquisition 2 Corp. (Name of Issuer) OrdinaryShares included as part of the Units (Title of Class of Securities) G2956R111 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement)

LAXXU / 8i Acquisition 2 Corp. Unit / Karpus Management, Inc. - KARPUS INVESTMENT MGT / 8I ACQUISITION 2 - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ????) * 8i Acquisition 2 Corp. (Name of Issuer) Common (Title of Class of Securities) G2956R103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Sc

LAXXU / 8i Acquisition 2 Corp. Unit / Tan Meng Dong Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ?240.13d-2 8i Acquisition 2 Corp. (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) G2956R 103 (CUSIP Number) November 24, 2021 (Date of Event w